ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.

Provided By PR Newswire

Last update: Feb 16, 2024

NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors concerning the proposed acquisition of the company by XOMA Corporation. Stockholders will receive between $2.3352 and $2.5879, as well as one contingent value right, for each share of Kinnate Biopharma stock that they hold. The transaction is expected to close in the first half of 2024.